One needs to recognize that results from cell lines and mouse models very frequently don't replicate in human trials.
Looks like your theory was blown out of the Fargo waters.... because who in their right mind aggressively goes after PS Targeting to hold it back as much as possible if things were not replicating in human trials : )
Doubling of MOS says things work just as planned and in Sunrise, all went as expected and expectations were not to run a phase III and not beat SOC
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!